#Canada #Duchesnay #Blainville #Women's Health #Slynd

Slynd Now Widely Available in Canada

Duchesnay Inc., a leader in women's health, proudly announced that its innovative contraceptive, Slynd (drospirenone tablets, 4 mg), is now accessible to 95% of the Canadian population through public insurance plans. This significant leap in access comes as a part of provincial reimbursement initiatives across various regions including British Columbia, Alberta, Manitoba, Ontario, New Brunswick, Nova Scotia, Yukon, and the Northwest Territories. Furthermore, Slynd is covered under federal programs that support Canadian Armed Forces members, veterans, and those eligible for Non-Insured Health Benefits. Private insurance plans are also on board, adding to the coverage available since Quebec's RAMQ included it in their plans last year.

Originally introduced to the market in 2022, Slynd represents 50 years of progress since the first progestin-only pill was released to the public. Duchesnay has committed itself to providing women with effective contraceptive options, and Slynd stands out as a crucial player in this mission. "As a woman, I could not be prouder of this announcement. It not only facilitates access to innovative medications but also ensures they are affordable, keeping women's health at the forefront of our objectives," stated Édith Sirard, Director of Sales and Marketing at Duchesnay.

The healthcare community has long emphasized the necessity for equitable access to contraceptive options to improve health outcomes significantly. Increased access enables women to make informed reproductive choices, which can decrease instances of unintended pregnancies and the health complications that accompany them. Dr. Amanda Black, former President of the Society of Obstetricians and Gynaecologists of Canada (SOGC), lauded the move, expressing, “Every woman in Canada should have access to a diverse range of contraceptive methods, as no single solution fits all. Removing financial barriers is essential for personal choice in contraceptive methods.”

Slynd stands out for its 24/4 dosing regimen, which includes 24 active tablets and four inactive ones, a cycle that can empower users with added convenience—particularly useful if a dose is missed within the specified 24-hour window, during which no alternative contraception is needed. Dr. Dustin Costescu, a Family Planning Specialist at McMaster University, emphasized the treatment's suitability for various women of reproductive age, indicating that the Ontario Drug Benefit’s support for Slynd marks a significant advance for patient care.

Importantly, Slynd is not suitable for women who have a known hypersensitivity to drospirenone or any of its components, nor is it recommended for those experiencing specific medical issues, including renal impairment or a history of progestin-sensitive cancers. More detailed information about contraindications, side effects, and usage can be found in the Product Monograph available through Duchesnay’s Medical Information Department.

About Duchesnay Inc.

Duchesnay Inc. has a rich history and a steadfast commitment to women’s health. Initially focused on developing safe pharmacological treatments for use during pregnancy and breastfeeding, Duchesnay has expanded its product lineup to include various therapeutic options tailored to women's health needs. The company believes that women everywhere deserve access to specialized health care solutions.

Duchesnay's dedication to pharmaceutical innovation has been recognized with the 2024 Life Sciences Innovation Award from the Association for the Development of Research and Innovation of Quebec (ADRIQ). Duchesnay continues to uphold strong values by fostering a positive work culture, innovating responsibly, and committing to community support through charitable engagement.

For more information about Duchesnay and its product offerings, please visit Duchesnay’s website.